Posted by Michael Wonder on 29 Dec 2020
Vertex announces new drug submission for investigational triple combination medicine for the treatment of cystic fibrosis has been accepted for priority review by Health Canada
28 December 2020 - Vertex Pharmaceuticals Incorporated today announced its New Drug Submission for Trikafta, Vertex’s investigational triple combination medicine, has been accepted for priority review by Health Canada for the treatment of cystic fibrosis in people ages 12 years and older.
The expected approval target by Health Canada is in the first half of 2021.
